Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi reports positive data from head-to-head Toujeo trial

Sanofi reports positive data from head-to-head Toujeo trial

4th December 2017

Sanofi has announced the findings of a new clinical trial that offers further evidence of the benefits its drug Toujeo can offer to type 2 diabetes patients.

The BRIGHT study compared Toujeo with insulin degludec and has already shown that Sanofi's drug was able to meet its primary objective of delivering blood sugar control effects similar to insulin degludec.

A total of 929 adults whose type 2 diabetes was previously uncontrolled on non-insulin medication have been enrolled in the study, which is still ongoing, with full results to be published at some point next year.

Secondary objectives include the percentage of patients experiencing adverse events, the total number of participants with low blood sugar events during the study, and the rate at which low blood sugar events occurred.

Long-acting insulins of this kind have already demonstrated significant blood glucose-lowering benefits, but hypoglycaemia remains a major limiting factor in effective blood sugar management, which is partly what this trial aims to assess.

Riccardo Perfetti, head of the global diabetes medical team at ‎Sanofi, said: "We believe that this first comparative clinical data assessing similarity and difference not only in efficacy, but also in the important safety aspect, such as low blood sugar events, can support physicians in their treatment decisions."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.